Access the full text.
Sign up today, get DeepDyve free for 14 days.
F. Silverstein, G. Faich, J. Goldstein, L. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N. Agrawal, W. Stenson, A. Burr, William Zhao, J. Kent, J. Lefkowith, K. Verburg, G. Geis (2000)
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.JAMA, 284 10
T. Kurth, Robert Glynn, Alexander Walker, K. Chan, Julie Buring, Charles Hennekens, J. Gaziano (2003)
Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory DrugsCirculation: Journal of the American Heart Association, 108
D. Henry, L. Lim, Luis Rodriguez, S. Gutthann, J. Carson, M. Griffin, R. Savage, R. Logan, Y. Moride, C. Hawkey, S. Hill, James Fries (1996)
Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysisBMJ, 312
N. Moore (2001)
PAIN 4406Comment on Tramer et al.Pain, 91
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M. Ferraz, C. Hawkey, M. Hochberg, T. Kvien, T. Schnitzer (2000)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.The New England journal of medicine, 343 21
J. Bradley, Kenneth Brandt, Kenneth Brandt, Barry Katz, L. Kalasinski, S. Ryan (1991)
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.The New England journal of medicine, 325 2
N. Moore (2001)
Comment on 'Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use' Tramer et al., Pain 2000;85:169-182.Pain, 91 3
M. Tramèr, R. Moore, D. Reynolds, H. McQuay (2000)
Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID usePain, 85
The risk related to the use of non-steroid anti-inflammatory drugs (NSAIDs) depends on the dose and duration of their use, in addition to the nature of the drug, and patient characteristics. The measures of risk and recent promotion of safer drugs have been mostly based on the results of clinical trials using continuous full-dose use of NSAIDs for periods up to 12 months which may not reflect real-life use and risks of the drugs. To assess this we did two studies of the utilisation of NSAIDs, one in a claims database to measure the amount of drugs dispensed to OA patients over 9 months, which showed that only a small fraction of patients actually bought enough analgesics or NSAIDs to cover the whole study period. On average, patients bought enough NSAIDs to cover 60 of 270 days. The second study was a survey of General Practitioners and rheumatologists to assess the number of users of NSAIDs seen over 2 days' consultations, the indications for and patterns of NSAIDs use. 11% of GP patients and 26% of rheumatologists' patients used NSAIDs, one-third for osteoarthritis (OA), about 8-10% for rheumatoid arthritis (RA) and the rest for various painful conditions. In OA and other conditions patients, more than 70% of patients had been taking their NSAIDs for less than 15 days at the time of consultation, whereas 42% of RA patients had been taking them for more than 6 months.
Inflammopharmacology – Springer Journals
Published: Dec 22, 2004
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.